Second Sight Medical Products (EYES) Stock Climbs Amid Receiving Grant From European Patent Office: Golden Opportunity?

On Monday, July 19, EYES’s stock was at $3.49. Nonetheless, it is gaining strong momentum, as the stock is skyrocketing: it is currently at $5.61 in the pre-market, resulting in a 61% gain. What is the reason behind this tremendous growth? The company has recently received a grant from European Patent Office for its patent application Orion Visual Cortical Prothesis System.


Orion Visual Cortical Prothesis System is an implanted cortical stimulation device, which intends to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury, or disease, and eye injury.

Second Sight Medical Products develops, manufactures, and markets implantable visual prosthetics that are intended to deliver the artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company was founded in 1998 and is headquartered in Sylmar, California.

Helen Larsen

After a long week of holidays in 2020, Helen realized she can do better in reporting Finance and Business news for Own Snap. Right now she is our weekend reporter and author. Sometimes she is busy with her projects that are related to her Master's Degree in Finance.

Want Hot Stocks?    Yes. I Love Them No thanks